Literature DB >> 29869107

Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study.

Li-Te Lin1,2,3, Salvatore Giovanni Vitale4,5, San-Nung Chen1, Zhi-Hong Wen6, Hsiao-Wen Tsai1,2, Chyi-Uei Chern1, Kuan-Hao Tsui7,8,9.   

Abstract

INTRODUCTION: Luteal phase ovarian stimulation (LPOS) has been proven a feasible protocol for infertile patients. High progesterone level in the luteal phase could physiologically inhibit premature luteinizing hormone surge, from which poor ovarian responders (PORs) could obtain benefits. Therefore, we aimed to compare clinical outcomes between LPOS and follicular phase ovarian stimulation (FPOS) protocol in PORs undergoing in vitro fertilization (IVF).
METHODS: This prospective pilot study was performed at one tertiary center from January 2016 to October 2017. A total of 60 PORs who met Bologna criteria and undergoing IVF were enrolled. Thirty PORs were allocated to the LPOS group and 30 PORs were allocated to the FPOS group. Basic characteristics, cycle characteristics, and pregnancy outcomes were compared between the two groups.
RESULTS: The length of stimulation was significantly longer in the LPOS group than in the FPOS group. The numbers of retrieved oocytes, metaphase II oocytes, fertilized oocytes, and day-3 embryos were significantly higher in the LPOS group than in the FPOS group. Conversely, we could not find any significant difference for clinical pregnancy rate, ongoing pregnancy rate, abortion rate, and cancellation rate. The multivariate analysis showed that only LPOS (p = 0.007) was significantly associated the possibility to retrieve three or more oocytes, whereas basal follicle-stimulating hormone (FSH) < 8 IU/l (p = 0.103) and antral follicle count (AFC) ≥ 3 (p = 0.143) did not significantly affect this event.
CONCLUSION: LPOS allows improved oocyte retrieval and oocyte quality in PORs with respect to FPOS, despite comparable pregnancy outcomes. LPOS may be considered a feasible option for oocytes accumulation in PORs. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03238833.

Entities:  

Keywords:  Antagonist protocol; Follicular phase ovarian stimulation; Gynecology; Luteal phase ovarian stimulation; Obstetrics; Ovarian reserve; Poor ovarian responders

Mesh:

Substances:

Year:  2018        PMID: 29869107     DOI: 10.1007/s12325-018-0713-1

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  10 in total

1.  How effective are the non-conventional ovarian stimulation protocols in ART? A systematic review and meta-analysis.

Authors:  Demian Glujovsky; Romina Pesce; Mariana Miguens; Carlos E Sueldo; Karinna Lattes; Agustín Ciapponi
Journal:  J Assist Reprod Genet       Date:  2020-11-21       Impact factor: 3.412

2.  Rescue In Vitro Maturation in Polycystic Ovarian Syndrome Patients Undergoing In Vitro Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study.

Authors:  Muhammad Fatum; Marie Eve Bergeron; Caroline Ross; Anni Ding; Ayesha Bhevan; Karen Turner; Tim Child
Journal:  Int J Fertil Steril       Date:  2020-07-15

3.  Dual stimulation in unexpected poor responder POSEIDON classification group 1, sub-group 2a: A cross-sectional study.

Authors:  Maryam Eftekhar; Banafsheh Mohammadi; Parisa Khani; Maryam Mortazavi Lahijani
Journal:  Int J Reprod Biomed       Date:  2020-06-30

Review 4.  ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis.

Authors:  Buo-Jia Lu; Chien-Ju Lin; Bou-Zenn Lin; Li Huang; Li-Ting Chien; Chi-Huang Chen
Journal:  J Assist Reprod Genet       Date:  2021-05-25       Impact factor: 3.357

5.  Development of a predictive model for luteal phase oocyte retrieval in poor responders undergoing natural cycle IVF.

Authors:  Mara Simopoulou; Dionysios Galatis; Evangelos Maziotis; Agni Pantou; Polina Giannelou; Sokratis Grigoriadis; Panagiotis Tzonis; Theodora Griva; Athanasios Zikopoulos; Anastasios Philippou; Michael Koutsilieris; Konstantinos Pantos; Konstantinos Sfakianoudis
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

6.  Follicular Output Rate and Follicle-to-Oocyte Index of Low Prognosis Patients According to POSEIDON Criteria: A Retrospective Cohort Study of 32,128 Treatment Cycles.

Authors:  Lijuan Chen; Hui Wang; Hanying Zhou; Haiyan Bai; Tao Wang; Wenhao Shi; Juanzi Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-07       Impact factor: 5.555

7.  Luteal phase stimulation versus follicular phase stimulation in poor ovarian responders: results of a randomized controlled trial.

Authors:  Joaquín Llácer; Belén Moliner; Lydia Luque; Andrea Bernabéu; Belén Lledó; Juan Carlos Castillo; Jaime Guerrero; Jorge Ten; Rafael Bernabéu
Journal:  Reprod Biol Endocrinol       Date:  2020-02-07       Impact factor: 5.211

8.  Efficacy of an Internet-Based Intervention to Promote a Healthy Lifestyle on the Reproductive Parameters of Overweight and Obese Women: Study Protocol for a Randomised Controlled Trial.

Authors:  Gemma Biviá-Roig; Ruth Blasco-Sanz; Ana Boldó-Roda; M Dolores Vara; Tamara Escrivá-Martínez; Rocío Herrero; Valentina Lucia La Rosa; Rosa M Baños; Juan Francisco Lisón
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

9.  Initial ovarian sensitivity index predicts embryo quality and pregnancy potential in the first days of controlled ovarian stimulation.

Authors:  David Camargo-Mattos; Uziel García; Felipe Camargo-Diaz; Ginna Ortiz; Ivan Madrazo; Esther Lopez-Bayghen
Journal:  J Ovarian Res       Date:  2020-08-17       Impact factor: 4.234

10.  DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review.

Authors:  Alberto Vaiarelli; Danilo Cimadomo; Cecilia Petriglia; Alessandro Conforti; Carlo Alviggi; Nicolò Ubaldi; Sergio Ledda; Susanna Ferrero; Laura Rienzi; Filippo Maria Ubaldi
Journal:  Ups J Med Sci       Date:  2020-04-25       Impact factor: 2.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.